JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced U.S. Food and Drug Administration (FDA) approval and commercial launch of its generic version of Galderma’s product, Differin® (adapalene 0.1%) Gel, which is indicated for the treatment of acne.
